BFC Planning’s Atea Pharmaceuticals AVIR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$521 Hold
100
– – ﹤0.01% 3283
2026
Q2
$465 Buy
+100
New +$497 ﹤0.01% 3259

Other funds holding AVIR

BFC Planning's AVIR Position: Q3 2026 in Review

BFC Planning held its Atea Pharmaceuticals (AVIR) position steady in Q3 2026 at 100 shares worth $521. The position accounts for ﹤0.01% of the portfolio, ranked #3283.

BFC Planning first reported a position in AVIR in Q2 2026 and has held it in 2 quarters since. 89 funds tracked by Wall St. Rank hold AVIR as of Q3 2026.

  • BFC Planning held 100 shares of Atea Pharmaceuticals worth $521 as of Q3 2026.
  • BFC Planning left its Atea Pharmaceuticals share count unchanged in Q3 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3283 holding.
  • BFC Planning first reported a position in Atea Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • 89 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.